Cancer - Kidney(구연) (E-092) Trends of First-line Targeted Therapy in Korean Patients with Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib versus Pazopanib, a Multicenter Study 계명대학교 동산병원, ¹경북대학교병원, ²영남대학교병원, ³대구가톨릭대학교병원, ⁴동국대학교 경주병원 신택준, 최민수, 김병훈, 김천일, 최석환¹, 김현태¹, 김태환¹, 권태균¹, 고영휘², 하윤수³, 박재신³, 권세윤⁴, 이경섭⁴ Objectives: There have been few reports on comparison between sunitinib and pazopanib as first-line targeted therapy in Korean metastatic ccRCC (clear cell renal cell carcinoma). We sought to analyze the treatment trends of metastatic ccRCC by comparing the effects and adverse events of sunitinib and pazopanib. Materials and Methods: Data of 357 metastatic RCC patients who received the sunitinib or pazopanib as the first-line targeted therapy from the Daekyung Oncology Study Group database was obtained and analyzed. Among these patients, patients who only clear cell type was confirmed after needle biopsy or nephrectomy were included, and patients who underwent target therapy for less than 3 months were excluded. Results: Of 251 patients who met the inclusion criteria, sunitinib and pazopanib group were identified in 156 (62 %) and 95 (38 %) patients, respectively. Pazopanib group was older (66 vs. 61 yr, p=0.001) and more symptomatic (65 vs. 52 %, p=0.037) and had more patients with Karnofsky performance status <80 (20 vs. 11 %, p=0.048) and fewer number of organ metastases (p=0.004) compared to sunitinib group. There was no significant difference in disease control rate (88 vs. 87 %, p=0.744), the median progression-free survival (19 vs. 15 mo, p=0.755) and overall survival (25 vs. 19 mo, p=0.842) between sunitinib and pazopanib. The most common grade 3/4 adverse events with sunitinib and pazopanib were anemia (5 %) and hand-foot syndrome (3 %), respectively. There was no significant difference between sunitinib and pazopanib in number of patients who experienced grade 3/4 adverse events (15 vs. 11 %, p=0.275). However, there were more patients who discontinued treatment due to only adverse events in sunitinib group compared to pazopanib group (12 vs. 3 %, p=0.020). Conclusions: In Korean metastatic ccRCC, pazopanib tended to be used in patients with poorer health status compared to sunitinib. Sunitinib and pazopanib had no significant difference in treatment effect and survival, but pazopanib had more tolerable adverse events. keywords : metastatic renal cell carcinoma, targeted therapy